Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
The List on MSN5h
What We Know About Bruce Springsteen's Wife Patti's Health IssuesPatti Scialfa revealed that she has been battling cancer for years. Here's what Bruce Springsteen's wife and bandmate has ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...
(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...
The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.
Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...
Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.
In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...
DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback